Clinical trials / NCT05130866
NCT05130866Phase 2, phase 3Terminated

Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas

Study sponsor: Recursion Pharmaceuticals Inc. · RXRX

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov recordCSV export · Pro
Primary completion2025-08-18Actual
Enrollment · participants25Actual
Source updated2026-08-17Last update listed in the registry record
Version history

Changes to this trial

Last 12 months
Pro unlocks the full available history and CSV export. View Pro features

· 6 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Compare wording
− Before

Measure: Progression-free survival (PFS) in Cohort A Measure: Progression-free survival (PFS) in Cohort B

+ After

Measure: Cohort A: Number of Participants with Progression-free survival (PFS) at 6 Months Measure: Cohort B: Number of Participants with PFS up to 3 years

Participant count type changed

− Before

Estimated

+ After

Actual

Enrollment · participant count changed

− Before

92 participants (planned)

+ After

25 participants (actual)

Completion date type changed

− Before

Estimated

+ After

Actual

Primary completion date changed

− Before

Jan 2027

+ After

18 Aug 2025

Recruitment status changed

− Before

Recruiting

+ After

Terminated

Check registry source